The purpose of this study is to examine patient experiences, health-related quality of life, and decision-making associated with PET imaging for prostate cancer. In particular, Prostate Specific Membrane Antigen (PSMA) PET, a new and more sensitive form of imaging that can help identify metastatic cancer earlier and more reliably.
The primary objective is to measure health related quality of life among patients with prostate cancer who are undergoing prostate specific membrane positron emission tomography (PSMA-PET) imaging. This will be assessed in four domains: cancer related anxiety, decisional conflict, health related quality of life (physical functioning) and health preferences. The secondary objective is to conduct longitudinal in-depth qualitative interviews to better explore patient experiences and perspectives on PET imaging. Study Design Investigators will conduct a longitudinal explanatory sequential mixed methods study consisting of two phases. In the first phase, serial quantitative psychological (anxiety, uncertainty) and HRQoL survey data from patients undergoing PET imaging in routine clinical care will be collected. In the second phase, a subset of patients from phase 1 who have completed initial surveys will be recruited and conduct longitudinal in-depth qualitative interviews to better explore patient experiences and perspectives on PET imaging. Patient clinical and sociodemographic data will be collected through automated extraction from the medical record (EPIC) into the REDcap database through collaboration with JDAT. For fields that are not populated via automated methods we will manually enter information via abstraction of the patient's medical record (EPIC).
Study Type
OBSERVATIONAL
Enrollment
350
Yale New Haven Health Bridgeport Hospital - Park Ave Medical Center
Bridgeport, Connecticut, United States
Griffin Hospital
Derby, Connecticut, United States
Yale New Haven Health Greenwich Hospital
Greenwich, Connecticut, United States
Radiology and Biomedical Imaging - New Haven - Smilow Cancer Hospital (North Pavilion):
Change in Memorial Anxiety Scale for Prostate Cancer (MAX-PC)
An 18-item instrument assessing frequency of anxiety in response to prostate cancer with 4 Likert responses ranging from 0 (not at all) to 3 (often); total score range 0 to 54). Higher scores indicate more anxiety.
Time frame: baseline, 3-6 months, and 12 months
Change in Decisional Conflict Scale (DCS)
A 16-item instrument using a 5-point Likert scale, ranging from 0 (strongly agree)-4 (strongly disagree), that has been widely applied to understand decision-making in prostate cancer. Higher scores indicate greater degrees of decisional conflict. DCS subscales include patient perceptions of uncertainty in choosing among treatment options, the contribution of modifiable factors (e.g., feeling uninformed), and effectiveness of decision-making (e.g., satisfaction with the choice). Total and subscale scores range from 0 to 100.
Time frame: baseline, 3-6 months, and 12 months
Change in Expanded Prostate Cancer Index Composite Short Form (EPIC-26)
A 26 item prostate cancer specific health-related quality of life (HRQOL) questionnaire assessing urinary incontinence, urinary irritative/obstructive, bowel, sexual and hormonal domains. Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing better HRQOL.
Time frame: baseline, 3-6 months, and 12 months
Change in EuroQol-5 Dimension (EQ-5D)
The instrument assesses five dimensions including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. EQ-5D values can be converted to calculate health utilities that will be used for estimation of quality adjusted life years in decision analytic modeling. EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3=moderate problems, 4= severe problems, and 5= extreme problems. Higher scores indicated greater levels of problems across each of the five dimensions. A utility score was obtained by using a weighted combination of the levels of the five dimension-scales.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
New Haven, Connecticut, United States
Saint Raphael's Radiology and Biomedical Imaging, Basement Location.
New Haven, Connecticut, United States
Yale New Haven Health Lawrence & Memorial Hospital
New London, Connecticut, United States
Yale New Haven Health Westerly Hospital
Westerly, Rhode Island, United States
Time frame: baseline, 3-6 months, and 12 months
Qualitative interviews on patient experiences and perspectives on PET imaging.
Longitudinal in-depth qualitative interviews to better explore patient experiences and perspectives on PET imaging to assess emergent themes. A subset of patients will be invited to participate in parallel in depth focused interviews occurring at three time points matching those of the surveys. Sample size will be dynamic and assessed based on emergent themes that become apparent during coding and analysis of interviews.
Time frame: baseline, 3-6 months, and 12 months